Skip to content
Study details
Enrolling now

Safety of Herpes Zoster Vaccine in Lupus

NYU Langone Health
NCT IDNCT05559671ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

224

Study length

about 3.6 years

Ages

18–90

Locations

2 sites in NY, OK

What this study is about

Researchers are testing the safety of a herpes zoster vaccine in people with lupus. The trial will evaluate whether this vaccine is safe and how well it works in individuals with varying levels of lupus activity, different ages, and exposure to immunosuppressant medications. Participants will receive either the vaccine or a placebo.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Herpes Zoster Subunit (HZ/su) Vaccine
  • 2.Receive Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

vaccine

Drug routes

injection

Endpoints

Secondary: Occurrence of Grade 3 or Higher Adverse Events as Per CTCAE or Solicited AIT within 24 Weeks of First Dosing with HZ/su Vaccine

Body systems

Immune